CTA-3
Explore the Latest Data in Advanced RCC Treatment
CTA-4
Another aRCC Option
See the selected safety profile of another OPDIVO-based combination for advanced RCC.
CTA-5
Another Advanced RCC Option
Learn more about another OPDIVO-based combination for advanced renal cell carcinoma.
CTA-7
NEW DATA
Explore the Latest Data in NSCLC
CTA-8
More NSCLC Indications
See selected safety profiles for other non-small cell lung cancer indications.
CTA-9
More NSCLC Indications
Learn how OPDIVO and OPDIVO-based combinations treat non-small cell lung cancer.
CTA-13
More Melanoma Options
Learn more about all melanoma indications.
CTA-14
More Melanoma Options
See selected safety profiles for other melanoma indications.
CTA-22
Dosing Schedules
Learn about dosing across all indications.
CTA-23.1
Dosing Schedules
Find dosing information to get patients started on therapy.
CTA-23.2
Dosing Schedules
Find dosing information to get patients started on therapy.
CTA-23.3
Dosing Schedules
Find dosing information to get patients started on therapy.
CTA-23.4
Dosing Schedules
Find dosing information to get patients started on therapy.
CTA-23.5
Dosing Schedules
Find dosing information to get patients started on therapy.
CTA-24
Dosing Information
Find the appropriate dosing information for your patients in any approved regimen.
CTA-25
Preparation and Administration
Find instructions for preparation, administration, infusion, and storage.
CTA-25.1
Preparation and Administration
Find instructions for preparation, administration, infusion, and storage.
CTA-26
Treatment Modifications
See recommended dosing modifications for immune-mediated adverse reactions.
CTA-26.1
Treatment Modifications
See recommended dosing modifications for immune-mediated adverse reactions.
CTA-39
Patient Monitoring Checklist
A convenient, printable tool to help nurses identify signs and symptoms of immune-mediated adverse reactions.
CTA-39.1
Patient Monitoring Checklist
A convenient, printable tool to help nurses identify signs and symptoms of immune-mediated adverse reactions.
CTA-43
OPDIVO Dosing Guide
A guide to dosing across all indications.
CTA-43.1
OPDIVO Dosing Guide
A guide to dosing across all indications.
CTA-48
IMAR Guide
A quick reference guide to immune-mediated adverse reactions (IMARs) associated with treatment.
CTA-48.1
IMAR Guide
A quick reference guide to immune-mediated adverse reactions (IMARs) associated with treatment.
CTA-49
Dual I-O Therapy Option
See dual I-O treatment results in metastatic melanoma, advanced RCC, and mNSCLC.
CTA-50
Earlier-Stage Treatment Option
Learn more about neoadjuvant use in resectable NSCLC, adjuvant use in UC, melanoma, and EC or GEJC, and perioperative use in NSCLC.
CTA-51
Advanced Melanoma Option
Learn about the latest option for patients with unresectable or metastatic melanoma.
CTA-54.1
More Gastroesophageal Indications
Learn more about other gastroesophageal indications across adjuvant and 1L metastatic settings.
CTA-54.2
More Gastroesophageal Indications
Learn more about other gastroesophageal indications across adjuvant and 1L metastatic settings.
CTA-55
More UC Indications
Learn about another urothelial carcinoma indication.
CTA-56
More UC Indications
See the selected safety profile of another urothelial carcinoma indication.
CTA-59
1L Unresectable or Metastatic Urothelial Carcinoma Option
OPDIVO, in combination with cisplatin and gemcitabine, is approved for the 1L treatment of adult patients with unresectable or metastatic urothelial carcinoma.
CTA-1
Explore the Latest Data in Gastroesophageal Cancer Treatment
CTA-26.1
Treatment Modifications
See recommended dosing modifications for immune-mediated adverse reactions.
CTA-25.1
Preparation and Administration
Find instructions for preparation, administration, infusion, and storage.
patient-checklist
Patient Monitoring Checklist
A convenient, printable tool to help nurses identify signs and symptoms of immune-mediated adverse reactions.
nccn
National Comprehensive Cancer Network® (NCCN®) Recommendations
An interactive resource that provides the latest NCCN recommendations for nivolumab (OPDIVO) and nivolumab-based combinations.
pocket-guide
Patient Pocket Guide
A guide that includes a compact wallet card and checklist for patients to recognize and report adverse reactions.
patient-website
From the OPDIVO Patient Website
The OPDIVO patient website offers a variety of resources and tools to help patients and caregivers better understand and navigate treatment.
CTA-12
See the Latest Data in Melanoma Treatment
CTA-19
Explore the Latest Data in UC Treatment
CTA-33
A NEW I-O Therapy Option
Discover the latest I-O–based combination therapy and how it may add to your therapy options.
CTA-34
A NEW OPDIVO-Based Option
Discover how the latest OPDIVO-based combination may add to your treatment options.
CTA-46
Discover Our Latest FDA Approval
Learn about our latest treatment option and explore the data.
CTA-53
NEW
Discover an FDA Approval
dualio_214
More Advanced RCC Data
See PFS and ORR data for OPDIVO + YERVOY.
dualio_227
More 1L mNSCLC (PD-L1 ≥1%) Data
See additional OS and response results for OPDIVO + YERVOY.
dualio_067
More Advanced Melanoma Data
See subgroup analyses and PFS results for OPDIVO + YERVOY.
cm9la
NEW DATA
1L r/m NSCLC
(PD-L1 <1% & ≥1%)
OPDIVO, in combination with YERVOY and 2 cycles of platinum-doublet chemotherapy, is indicated for the first-line treatment of adult patients with metastatic or recurrent non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations.
cm227
1L mNSCLC (PD-L1 ≥1%)
OPDIVO, in combination with YERVOY, is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1 (≥1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations.
cm77t
NOW APPROVED
Perioperative NSCLC
OPDIVO, in combination with platinum-doublet chemotherapy, is indicated for the neoadjuvant treatment of adult patients with resectable (tumors ≥4 cm or node positive) NSCLC and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements, followed by single-agent OPDIVO as adjuvant treatment after surgery.
cm816
NEW DATA
Neoadjuvant Treatment of Resectable NSCLC
OPDIVO, in combination with platinum-doublet chemotherapy, is indicated as neoadjuvant treatment of adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer (NSCLC).
cm017_057
2L mNSCLC
OPDIVO is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO.
cm214
1L Intermediate- or Poor-Risk aRCC
OPDIVO, in combination with YERVOY, is indicated for the first-line treatment of adult patients with intermediate- or poor-risk advanced renal cell carcinoma (aRCC).
cm9er
1L Advanced RCC
OPDIVO, in combination with cabozantinib, is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma (aRCC).
CM577
NOW APPROVED
Perioperative NSCLC
OPDIVO, in combination with platinum-doublet chemotherapy, is indicated for the neoadjuvant treatment of adult patients with resectable (tumors ≥4 cm or node positive) NSCLC and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements, followed by single-agent OPDIVO as adjuvant treatment after surgery.
CM901_Efficacy
1L Unresectable or Metastatic UC
OPDIVO, in combination with cisplatin and gemcitabine, is indicated for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma.
CM274_Efficacy
Adjuvant Treatment of UC
OPDIVO, as a single agent, is indicated for the adjuvant treatment of adult patients with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing radical resection of UC.
CM275_Efficacy
2L Locally Advanced or Metastatic UC
OPDIVO is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.
ESOC_77T
NOW APPROVED
Perioperative NSCLC
OPDIVO, in combination with platinum-doublet chemotherapy, is indicated for the neoadjuvant treatment of adult patients with resectable (tumors ≥4 cm or node positive) NSCLC and no known EGFR mutations or ALK rearrangements, followed by single-agent OPDIVO as adjuvant treatment after surgery.1
ESOC_816
Neoadjuvant treatment of resectable NSCLC
OPDIVO, in combination with platinum-doublet chemotherapy, is indicated as neoadjuvant treatment of adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer (NSCLC).1
ESOC_274
Adjuvant treatment of UC
OPDIVO, as a single agent, is indicated for the adjuvant treatment of adult patients with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing radical resection of UC.1
ESOC_76K_238
Adjuvant treatment of melanoma
OPDIVO is indicated for the adjuvant treatment of adult and pediatric patients 12 years and older with completely resected Stage IIB, Stage IIC, Stage III, or Stage IV melanoma.1
ESOC_577
Adjuvant treatment of EC or GEJC
OPDIVO is indicated for the adjuvant treatment of completely resected esophageal cancer (EC) or gastroesophageal junction cancer (GEJC) with residual pathologic disease in adult patients who have received neoadjuvant chemoradiotherapy (CRT).1
CM238_Efficacy
Adjuvant Treatment of Melanoma
OPDIVO is indicated for the adjuvant treatment of adult and pediatric patients 12 years and older with completely resected Stage III or Stage IV melanoma.
CM238_Safety
Adjuvant Treatment of Melanoma
OPDIVO is indicated for the adjuvant treatment of adult and pediatric patients 12 years and older with completely resected Stage III or Stage IV melanoma.
CTA-54
NOW AVAILABLE
Subcutaneous Injection Treatment Option
OPDIVO QvantigTM (nivolumab + hyaluronidase-nvhy) is now approved as a 3-5 minute subcutaneous injection.
Adjuvant Treatment of Melanoma
OPDIVO is indicated for the adjuvant treatment of adult and pediatric patients 12 years and older with completely resected Stage III or Stage IV melanoma.